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The ability of Staphylococcus aureus Cowan I strain and a number of S. aureus clinical isolates to bind to the
human blood glycoprotein clusterin was investigated. Binding of clusterin to these strains was tested by both
enzyme-linked immunosorbent assay and flow cytometry. All of the S. aureus strains examined appeared to bind
clusterin to some extent, while nonpathogenic control strains Bacillus subtilis BR151 and Escherichia coli JM109
did not. Three S. aureus isolates were selected for more detailed study; binding of labeled clusterin was
saturable, inhibited in the presence of excess unlabeled clusterin, and prevented by pretreatment of bacteria
with proteases. From the saturation binding studies, estimates of the affinity constants for the binding of
clusterin to the bacteria ranged from 31 to 57 nM. Addition of clusterin to S. aureus cultures was also found
to result in aggregation of the bacterial cells; aggregation was not detected when clusterin was added to B.
subtilis BR151 or E. coli JM109 cultures. These results suggest that at least some S. aureus strains possess
specific proteinaceous receptors for clusterin. Such receptors may be an important new bacterial virulence
determinant for S. aureus, as clusterin has been proposed to have a role in the regulation of complement
activity.
Many species of pathogenic bacteria have been found to
possess specific cell surface receptors for various host proteins.
Interactions between host proteins and bacteria may contrib-
ute to bacterial pathogenicity in a number of ways. Staphylo-
coccus aureus is a major human pathogen, associated with
conditions ranging from localized superficial infections to se-
vere systemic diseases such as endocarditis, osteomyelitis, and
toxic shock syndrome (34). Various S. aureus strains have been
found to bind different host proteins, and in some cases specific
receptor proteins have been identified. The best known of
these receptors is protein A, which binds to the Fc regions of
antibodies (10), preventing their interaction with receptors on
phagocytic cells and thereby protecting the bacteria from
phagocytosis (7). S. aureus receptors for the extracellular ma-
trix proteins collagen (30), fibrinogen (23), and fibronectin (9,
15, 35) have been identified, and receptor genes have been
cloned and sequenced. Receptor proteins binding bone sialo-
protein (39) and vitronectin (20) have also been isolated from
S. aureus strains, and an S. aureus laminin-binding protein has
been identified (21). Receptors for extracellular matrix pro-
teins appear to be important in initial adhesion of the bacterial
cells to tissues, and differential expression of receptors for
matrix proteins with specific tissue distribution may partly ex-
plain the tissue tropism of infections caused by various staph-
ylococcal strains (29). A plasminogen receptor has also been
identified on S. aureus Cowan I (16), and plasmin bound to S.
aureus has been found to influence bacterial adherence (17).
Receptors for the iron-binding proteins lactoferrin and trans-
ferrin, which contribute to host defenses by limiting the avail-
ability of an essential microbial nutrient, have also been iso-
lated from S. aureus strains (24, 26).
Clusterin is a 70- to 80-kDa glycoprotein composed of two
similar-size subunits linked by five disulfide bonds (3, 5). Se-
quence analysis predicts that each chain contains amphipathic
a-helices and heparin binding sites (5). Clusterin is highly
conserved among mammalian species (14) and is present in
almost all tissues, including normal human plasma (at about 50
to 100 mg/ml [25]). This wide tissue and species distribution
suggests that clusterin has important functions, but its precise
physiological role(s) remains unknown (14). Clusterin was
originally identified as a protein able to cause aggregation of
Sertoli cells in ram testis fluid (11). Isolation of a clusterin
homolog in association with high-density lipoprotein particles
led to the suggestion of a role in lipid transport (6). Increased
clusterin levels also seem to be associated with tissue damage
and cells undergoing programmed cell death (apoptosis) (14).
Human clusterin was first identified as a protein found in the
SC5b-9 complex of complement (25), and a role for clusterin in
protecting cells from lysis by the terminal complement mem-
brane attack complex has been proposed (13). Clusterin has
also been demonstrated to interact with immunoglobulins by a
multivalent mechanism, binding to both the Fc and Fab re-
gions (38).
Several of the properties and proposed functions of clusterin
suggest that possession of clusterin receptors could contribute
to bacterial pathogenicity. We have therefore investigated
whether S. aureus Cowan I and a selection of clinical isolates
are capable of binding human clusterin. The S. aureus strains
tested appear to express cell surface receptors for clusterin,
which are proteins or are associated with proteins and which
mediate clusterin-induced aggregation of bacterial cells.
MATERIALS AND METHODS
Bacterial strains. Bacillus subtilis BR151 (19) and Escherichia coli JM109 (40)
were used as negative controls in clusterin binding experiments. S. aureus Cowan
I, a protein A-producing strain originally isolated from a patient with septic
arthritis (2), was obtained from the Australian Collection of Microorganisms,
University of Queensland. All other S. aureus strains were supplied by Southern
Pathology, Wollongong, New South Wales, Australia. All of the strains were
obtained from swabs of various infections as follows: 19, skin infection; 20,
abdominal wound infection; 21, infected leg; 22, infected toe; 36b, infected ear;
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and 55, infected wound. Strains were routinely grown at 378C in 23 LB medium
or on LB plates (32).
Preparation of bacterial cells. Single colonies were used to inoculate 10 ml of
23 LB medium (32), and the cultures were incubated at 378C in an orbital air
shaker for approximately 16 h. Cells harvested from 1 to 10 ml of these cultures
were washed three times in 1 ml of phosphate-buffered saline (PBS) containing
0.1% NaN3 and resuspended in 1 ml of PBS–0.1% NaN3. The A600s of the
suspensions of washed bacteria were then determined.
Immunoaffinity preparation of clusterin. Clusterin was prepared from frozen
human serum packs (Red Cross Blood Bank, Sydney, New South Wales, Aus-
tralia) by immunoaffinity chromatography, using a previously described mouse
monoclonal anti-human clusterin antibody (G7 [25]). Serum was thawed rapidly,
and EDTA, tetrasodium salt (to 10 mM), and phenylmethylsulfonyl fluoride (to
at least 1 mM) were added. The chilled serum was then filtered first through
Avantec Toyo no. 1 filter paper and second through a Whatman GF/C filter. The
filtered serum was loaded onto a G7-Sepharose column preequilibrated with
PBS containing 0.02% NaN3. After a wash with PBS–0.02% NaN3–0.5% Triton
X-100 to remove lipids and apolipoproteins, clusterin was eluted from the col-
umn with 2 M guanidine hydrochloride in PBS (pH 7.4). The eluted protein was
dialyzed at 48C overnight against PBS and passed over a protein G-Sepharose
column to remove clusterin-immunoglobulin G complexes (38). The unbound
fraction, which contained clusterin, was collected, concentrated by centrifugation
through a Filtron Macrospec centrifugal concentrator (10-kDa cutoff), and
checked for purity by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
The concentration of clusterin was determined by using the bicinchoninic acid
assay (36). Typically, about 10 to 12 mg of purified clusterin was obtained from
200 ml of serum.
Biotinylation and FITC labeling of proteins. Clusterin preparations were di-
alyzed against carbonate-bicarbonate buffer (0.1 M Na2CO3, 0.1 M NaHCO3
[pH 8.5]), while bovine serum albumin (BSA; Sigma) was dissolved directly in
this buffer. Protein solutions were used at approximately 1 mg/ml. For biotiny-
lation, biotinamidocaproate N-hydroxysuccinimide ester (Sigma) was added
from a stock solution (40 mg/ml in dimethyl sulfoxide) to approximately 200 mg
of the ester per mg of protein to be labeled. For fluorescein isothiocyanate
(FITC) labeling, FITC (Sigma) was added from a solution freshly made in
dimethyl sulfoxide to approximately 250 mg of FITC per mg of protein. For both
labeling procedures, the reaction mixtures were incubated at room temperature
for 1 to 2 h on a rocking platform. Excess unbound label was removed by
overnight dialysis against PBS at 48C. In the case of FITC labeling, the reaction
mixture was protected from light during both the incubation and dialysis steps.
The final concentration of the labeled protein was determined by using the
bicinchoninic acid assay (36).
ELISA. Appropriate amounts of bacterial cells were pelleted and resuspended
to give an A600 of 3.0 in 0.3% methyl glyoxal (pH 8.0), which aids adhesion of
bacterial cells to enzyme-linked immunosorbent assay (ELISA) plates (4). Ali-
quots (50 ml) of bacterial suspensions were dispensed into ELISA plates (Dis-
posable Products, Adelaide, South Australia, Australia), and the plates were
incubated at 378C for 90 min. After six washes with PBS in a Bio-Rad model 1250
Immunowash plate washer, nonspecific binding to the wells was blocked by
incubation with 1% heat-denatured casein in PBS (HDC) for 60 min at 378C.
Biotinylated or unlabeled clusterin in HDC was then added to the plates as
required, and the plates were incubated for 60 min at 378C. The plates were
washed as described above between incubations except that for competition
experiments, biotinylated clusterin was added to unwashed wells preincubated
with unlabeled clusterin. Bound biotinylated clusterin was detected by addition
of streptavidin-horseradish peroxidase conjugate (SA-HRP; 0.2 mg/ml in HDC;
Sigma) and incubation for 30 min at 378C. Plates were then washed once with
PBS–0.1% Triton X-100 (by shaking for 5 min on a plate shaker) and then
washed five times with PBS–Triton X-100 (without shaking). Bound SA-HRP
was detected by adding to each well 100 ml of o-phenylenediamine (OPD)
reagent (2.5 mg of OPD per ml and 1 ml of 30%H2O2 per ml in citrate buffer [0.1
M Na2HPO4, 0.05 M citric acid, pH 5.0]), and the reaction was stopped after 3
to 10 min by addition of 50 ml of 1 M HCl per well. Plates were read immediately
on a Bio-Rad model 3550 plate reader at 490 nm.
Calculation of binding affinities and statistical analysis. The apparent disso-
ciation constants (Kds) for the binding of clusterin to the bacteria were estimated
from curve fits obtained by using Kaleidagraph (Abelbeck Software), a nonlinear
regression analysis program which uses the Levenberg-Marquardt algorithm. For
the saturation curve, data were analyzed by fitting the equation of noncoopera-
tive binding: absorbance5m1/(1.01m2/[clusterin]), wherem1 is the amount of
clusterin bound at saturating levels and m2 is the apparent affinity constant for
biotinylated clusterin in micrograms per milliliter. For the t test, the equation
used was t 5 [m1(1) 2 m1(2)]/[sqrt(SE(1)∧2 1 SE(2)∧2)] for (n1 1 n2 2 4)
degrees of freedom, where m1(1) and m1(2) are fitted values for the parameters
for data sets 1 and 2, SE(1) and SE(2) are the standard errors for the fitted
values, and n1 and n2 are the numbers of datum points in data sets 1 and 2.
Flow cytometry. Bacterial cells prepared as for ELISA were resuspended in
100 ml of PBS or a solution of the appropriate FITC-labeled protein to an A600
of 3.0 and incubated for 30 to 60 min at 378C in the dark. The cells were then
pelleted, washed twice with 1 ml of PBS, resuspended in 0.5 ml of FACSfix (1%
paraformaldehyde in PBS [pH 7.4]), and stored at 48C in the dark. Samples were
analyzed on a Becton Dickinson FACSort flow cytometer set as follows: FSC
E01, 9.000 log scale; SSC 366, 1.00, log scale; and FL1, 933, 1.00, log scale. Gating
was used to collect data from bacterial cells and to exclude any background
debris. The position, shape, and size of the gate were changed as required to
accommodate differences between the populations of S. aureus cells and those of
the control strains. Data from 10,000 events were collected for all samples. In
some cases, samples of bacterial cells were incubated with unlabeled clusterin,
then tissue culture supernatant from cells expressing G7 (a mouse anti-human
clusterin antibody [25]) or DNP9 (an isotype-matched control antibody raised
against the 2,4-dinitrophenyl group [38]), and finally FITC-conjugated sheep
anti-mouse antibody (diluted 1:50 in PBS; Silenus, Melbourne, Victoria, Austra-
lia). In these cases, all of the solutions used contained rabbit immunoglobulin G
at 250 mg/ml, which had been found to effectively block Fc binding of antibodies
by S. aureus cell surface protein A (results not shown). Samples were then
analyzed as described above.
Protease treatment of bacteria. Pronase (50 mg/ml) or trypsin (250 mg/ml) was
added to suspensions of washed bacterial cells (A600 adjusted to approximately
1.5 in PBS), and the suspensions were incubated at 378C with shaking for 2 h. The
cells were then pelleted, washed twice with 1 ml of PBS, resuspended in FITC-
labeled clusterin (20 mg/ml) to a calculated A600 of 3.0, incubated for 30 to 60 min
at 378C, washed, and analyzed by flow cytometry as described above.
Light microscopy. Bacterial cell samples for microscopy were resuspended in
50 ml of PBS, BSA (100 mg/ml), or clusterin (5 to 100 mg/ml) to an A600 of 3.0 and
incubated at 378C for 60 min. The cells were then washed once with PBS,
resuspended in 100 ml of FACSfix, observed under a Leitz Dialux 22 microscope,
and photographed.
RESULTS
Screening of S. aureus strains for clusterin binding. Initial
screening of S. aureus strains for clusterin binding ability was
carried out by ELISA and flow cytometry. The nonpathogenic
bacterial strains B. subtilis BR151 and E. coli JM109 were used
as negative controls, as these strains were not expected to bind
human proteins. For ELISA, biotinylated clusterin (10 mg/ml
in HDC) was added to wells containing bound bacteria or
previously incubated with methyl glyoxal alone. Initially, adhe-
sion of bacterial cells to ELISA plates was checked microscop-
ically following staining of cells with carbol fuchsin (results not
shown). Figure 1 summarizes the results of screening of the
negative control strains and seven S. aureus strains. All of the
S. aureus strains tested except 55 bound much higher levels of
FIG. 1. ELISA screening of bacterial strains for the ability to bind clusterin.
Samples of seven S. aureus strains, and B. subtilis BR151 and E. coli JM109 as
negative controls, bound to ELISA trays were incubated with biotinylated clus-
terin at 10 mg/ml and then with SA-HRP and OPD. Each bar represents the
mean of six measurements, three from each of two separate cultures. The error
bars represent 1 standard deviation of the mean.
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biotinylated clusterin than either of the two negative control
strains.
For flow cytometry, samples of bacteria cells were incubated
in either PBS, BSA-FITC (20 mg/ml), or clusterin-FITC (20
mg/ml). Treatment of all samples with the negative control
protein BSA-FITC resulted in levels of fluorescence similar to
those seen following incubation in PBS alone (results not
shown). Treatment of the B. subtilis and E. coli control strains
with clusterin-FITC also resulted in essentially the same level
of fluorescence as treatment with PBS or BSA-FITC (Fig. 2A
and B), confirming that these strains do not bind clusterin. In
contrast, S. aureus Cowan I, 21, and 36b (Fig. 2C to E, respec-
tively) and 19, 20, and 22 (results not shown) incubated with
clusterin-FITC all showed greater fluorescence than those in-
cubated with PBS or BSA-FITC, in agreement with the ELISA
results indicating that these strains bind clusterin. S. aureus 55
appeared to bind a low level of clusterin, much less than the
other S. aureus strains (Fig. 2F). The results shown are repre-
sentative of several repeated experiments.
To confirm that it was clusterin, rather than a colabeled
minor contaminant, binding to the bacteria, unlabeled clus-
terin in conjunction with a clusterin-specific monoclonal anti-
body (G7 [25]) was used. Specific binding of unlabeled clus-
terin to S. aureus Cowan I and other S. aureus strains which
bound biotinylated clusterin was confirmed (results not
shown).
These results indicate that some S. aureus strains are capable
of binding clusterin and that ELISA and flow cytometry are
suitable methods for screening strains of pathogenic bacteria
for the ability to bind host proteins. Strains Cowan I, 21, and
36b were selected for further study of clusterin binding inter-
actions.
Affinity of clusterin binding to selected S. aureus strains.
The affinity of clusterin binding to selected S. aureus strains
was investigated by ELISA. Increasing concentrations of bio-
tinylated clusterin in the range 0 to 25 mg/ml were added to
samples of strains Cowan I, 21, and 36b bound to ELISA
plates. Figure 3A shows that all three strains show saturable
binding of clusterin, suggesting that clusterin binding to S.
aureus strains is mediated by specific receptors. The results
shown are representative of several repeated experiments.
Analysis of the data indicated that there is a single class of
clusterin binding sites on each strain, and estimated Kd values
were 31.50 6 13.00, 38.75 6 19.25, and 56.13 6 22.00 nM for
strains Cowan I, 21, and 36b, respectively. When analyzed
statistically, there appeared to be no significant difference be-
tween the Kd values for the three strains, although strains
FIG. 2. Screening of bacterial strains by flow cytometry for the ability to bind
clusterin. Samples of B. subtilis BR151 (A), E. coli JM109 (B), and S. aureus
Cowan I (C), 21 (D), 36b (E), and 55 (F) were treated with BSA-FITC (20 mg/ml;
thin lines) or clusterin-FITC (20 mg/ml; thick lines), washed, and analyzed by
flow cytometry.
FIG. 3. Binding of clusterin to strains Cowan I, 21, and 36b is saturable and
inhibited by excess unlabeled clusterin. (A) Samples of S. aureus Cowan I
(squares), 21 (circles), and 36b (triangles) bound to ELISA plates were incubated
with increasing concentrations of biotinylated clusterin in the range 0 to 25
mg/ml. Bound clusterin was detected with SA-HRP and OPD. Each datum point
represents the mean of three measurements, and error bars represent 1 standard
deviation of the mean. (B) Samples of S. aureus Cowan I, 21, and 36b bound to
ELISA plates were incubated with HDC (filled columns) or unlabeled clusterin
(2 mg/ml; open columns). Biotinylated clusterin was then added to a final con-
centration of 10 mg/ml. After incubation and washing, bound biotinylated clus-
terin was finally detected with SA-HRP and OPD. Each datum point represents
the mean of three measurements, and error bars represent 1 standard deviation
of the mean.
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Cowan I and 21 appear to have more clusterin binding sites per
cell than strain 36b.
To confirm that interaction of clusterin with these staphylo-
coccal strains is specific, cells of strains Cowan I, 21, and 36b
bound to ELISA plates were preincubated with excess unla-
beled clusterin, and then biotinylated clusterin was added to a
final concentration of 10 mg/ml. Figure 3B shows that excess
unlabeled clusterin inhibits binding of biotinylated clusterin to
these three strains. The results shown are representative of
several repeated experiments.
Effect of protease treatment on binding of clusterin to se-
lected S. aureus strains. The results of saturation and compe-
tition studies suggested that clusterin binds to S. aureus Cowan
I, 21, and 36b via specific receptors. The effect of protease
treatment on binding of FITC-clusterin to these three strains
was therefore investigated to determine whether these recep-
tors could be proteins. A similar method has previously been
used to demonstrate that a proteinaceous receptor is respon-
sible for plasminogen binding to S. aureus Cowan I (16). Sam-
ples of bacterial cells that had been preincubated with pronase
or trypsin, washed, and incubated with FITC-labeled clusterin
were analyzed by flow cytometry. Figure 4 shows that such
treatment of S. aureus Cowan I, 21, and 36b with either pro-
tease virtually abolished clusterin binding. Pretreatment of
these same strains with PBS without added protease had no
significant effect on clusterin binding (results not shown).
These results suggest that the putative clusterin receptors ex-
pressed by these strains are proteins or are associated with
proteins.
Clusterin-mediated aggregation of S. aureus cells. While
studying the binding of clusterin to S. aureus strains by flow
cytometry, we observed that samples of bacterial cells incu-
bated with various concentrations of clusterin contained par-
ticles with increased forward scatter and side scatter compared
with samples incubated in PBS or similar concentrations of
BSA (results not shown). A possible explanation for this effect
was that clusterin causes aggregation of cells of these strains.
To further investigate this effect, bacteria that had been incu-
bated in PBS or in various concentrations of BSA or clusterin
were examined by light microscopy. Cell aggregates were seen
in S. aureus Cowan I samples that had been incubated in
clusterin (Fig. 5A) but not in samples incubated in PBS alone
(results not shown) or in PBS containing similar concentra-
tions of BSA (Fig. 5B). The aggregating ability of clusterin
appeared to correlate with clusterin binding ability of the cells,
as B. subtilis BR151 and E. coli JM109 did not form clumps,
even at high clusterin concentrations (up to 2 mg/ml; results
not shown).
DISCUSSION
Using both biotinylated clusterin in an ELISA and FITC-
labeled clusterin in flow cytometry, we have shown that at least
some S. aureus strains are able to bind human clusterin,
FIG. 4. Binding of FITC-labeled clusterin to selected S. aureus strains is
inhibited by pretreatment of bacteria with proteases. Samples of S. aureus Cowan
I (A and B), 21 (C and D), and 36b (E and F) were treated with trypsin (250
mg/ml; A, C, and E) or pronase (50 mg/ml: B, D, and F). After being washed,
these samples were then incubated with clusterin-FITC (dotted lines) and com-
pared with untreated samples incubated with clusterin-FITC (20 mg/ml; thick
lines) or BSA-FITC (20 mg/ml: thin lines) by flow cytometry.
FIG. 5. Clusterin-mediated aggregation of S. aureus cells. Samples of cells
from cultures of S. aureus Cowan I were incubated in clusterin (100 mg/ml in
PBS; A) or BSA (100 mg/ml in PBS; B) and examined microscopically, using a
1003 objective lens and 12.53 eyepiece.
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whereas two nonpathogenic species do not. For three strains
(Cowan I, 21, and 36b) investigated in more detail, this binding
appears to be mediated by specific receptors, which are pro-
teins or are associated with proteins. The apparent dissociation
constant for the binding of biotinylated clusterin to these re-
ceptors was estimated to be in the range 31 to 57 nM. The
levels of clusterin found in normal human plasma (approxi-
mately 625 to 1,250 nM [25]) are thus well above the concen-
tration required to saturate the receptors, indicating that clus-
terin binding could be physiologically relevant. Recently, a
Streptococcus pyogenes secreted protein (SIC protein) which
binds to clusterin has been identified (1); dot blot analysis
indicates that some clusterin binding activity may also be
present in media in which S. aureus Cowan I has been grown
(27).
Previous workers have generally investigated binding of host
proteins to bacterial cells by incubating the cells with 125I-
labeled proteins and measuring the radioactivity associated
with cell pellets. The ELISA and flow cytometric methods that
we have used have certain advantages over this method: bio-
tinylated and FITC-labeled proteins are simpler and safer to
prepare than iodinated proteins, the 96-well layout of ELISA
plates allows easy simultaneous screening of many strains, and
flow cytometry gives information on individual cells rather than
cell populations, allowing the possibility of analyzing subpopu-
lations of cells. We have also used these methods to demon-
strate that some bacterial clinical isolates bind plasminogen, in
agreement with previous results (22), and to screen strains
other than S. aureus for clusterin binding ability (27).
Although these studies indicate that some S. aureus strains
appear to express clusterin receptors, we have not yet deter-
mined how possession of such receptors could influence bac-
terial pathogenicity. An obvious starting point would be the
proposed role of clusterin as a regulator of complement activ-
ity. The recently identified clusterin-binding SIC protein was
found to be incorporated into the terminal C5b-C9 comple-
ment complexes formed in serum and to inhibit complement-
mediated lysis of erythrocytes (1). As gram-positive strains,
such as S. aureus and S. pyogenes, are resistant to lysis by the
complement membrane attack complex, clusterin bound to the
bacterial cell surface apparently would have to influence other
aspects of clusterin action to affect pathogenicity. Åkesson et
al. (1) suggested that SIC could influence the host-pathogen
relationship by affecting other functions of the membrane at-
tack complex, such as stimulation of the production and re-
lease of inflammatory mediators. Another aspect of antibacte-
rial complement activity which could be influenced by clusterin
is opsonization. Deposition of complement components such
as C3b on the bacterial surface results in enhanced phagocy-
tosis of both gram-negative and gram-positive bacteria. Clus-
terin bound to specific receptors on the bacterial cell surface
could prevent deposition of opsonizing molecules on the bac-
teria, providing protection against complement-mediated op-
sonization. Pathogenic bacteria are known to have mechanisms
for resisting the opsonizing effects of complement, for exam-
ple, the antiphagocytic M proteins of streptococci (8).
It is also possible that the cell aggregating action of clusterin
can influence bacterial pathogenicity. Clusterin has previously
been shown to cause aggregation of various types of eukaryotic
cells when suspended in PBS, but the effect was not reproduc-
ible when the cells were suspended in solutions containing
other serum proteins in addition to clusterin (11). It has been
known for some time that S. aureus cells form clumps in the
presence of plasma, and this effect can mainly be attributed to
interaction of fibrinogen with an S. aureus fibrinogen receptor
known as clumping factor (12). Fibronectin, laminin, and type
IV collagen can also mediate aggregation of S. aureus cells
(37). Such aggregation may allow bacteria to elude phagocytic
host defenses, and it has been demonstrated that the ability of
S. aureus strains to aggregate in the presence of fibronectin
correlates with invasiveness (31).
It is clearly possible that the ability of S. aureus strains to
bind clusterin could contribute to the virulence of these strains.
Binding of other host proteins via specific receptors has been
found to correlate with increased virulence in a number of
cases. For example, inactivation of a S. aureus gene encoding a
collagen receptor has been found to result in a dramatic re-
duction in virulence in a mouse model of septic arthritis (28).
Furthermore, a strain of S. aureus which demonstrated de-
creased adherence to immobilized fibronectin, as a result of
transposon mutagenesis, was found to be less virulent than the
parental strains in a rat model of infective endocarditis (18). In
the case of the streptococcal SIC protein, it was found that only
certain group A streptococcal strains, those that are associated
with severe and toxic infections, contained and expressed the
sic gene, suggesting that the SIC protein may influence patho-
genicity (1).
In addition to investigating the possible roles of cell surface-
bound clusterin in bacterial pathogenicity, experiments aimed
at identifying and isolating clusterin receptor proteins and
cloning and sequencing the corresponding genes are currently
under way. The availability of cloned clusterin receptor genes
and corresponding sequence data would provide the basis for
the creation of mutations in clusterin receptor genes and for
studying the effects of these mutations on pathogenicity. The
results of these studies, plus the availability of purified clus-
terin receptor proteins, may also provide information useful
for designing new strategies to combat bacterial infections. The
characterized receptors could provide potential targets for the
action of new drugs (29). Alternatively, the receptor itself
could be used as a vaccine component, which not only would
act as an antigen in the normal immune response but also
could block receptor-ligand binding. Such strategies have al-
ready been tested by using other bacterial receptors for host
proteins, particularly receptors for extracellular matrix pro-
teins (e.g., reference 33). In the face of increased bacterial
resistance to traditional antibiotics, these therapeutic strate-
gies are likely to become increasingly important in fighting
bacterial infections.
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